Background: The Multimodal Treatment Study (MTA) began as a 14-month randomized clinical trial of behavioral and pharmacological treatments of 579 children (7-10 years of age) diagnosed with attention-deficit/hyperactivity disorder (ADHD)-combined type. It transitioned into an observational long-term follow-up of 515 cases consented for continuation and 289 classmates (258 without ADHD) added as a local normative comparison group (LNCG), with assessments 2-16 years after baseline. Methods: Primary (symptom severity) and secondary (adult height) outcomes in adulthood were specified. Treatment was monitored to age 18, and naturalistic subgroups were formed based on three patterns of long-term use of stimulant medication (Consistent, Inconsistent, and Negligible). For the follow-up, hypothesis-generating analyses were performed on outcomes in early adulthood (at 25 years of age). Planned comparisons were used to estimate ADHD-LNCG differences reflecting persistence of symptoms and naturalistic subgroup differences reflecting benefit (symptom reduction) and cost (height suppression) associated with extended use of medication. Results: For ratings of symptom severity, the ADHD-LNCG comparison was statistically significant for the parent/self-report average (0.51 AE 0.04, p < .0001, d = 1.11), documenting symptom persistence, and for the parent/self-report difference (0.21 AE 0.04, p < .0001, d = .60), documenting source discrepancy, but the comparisons of naturalistic subgroups reflecting medication effects were not significant. For adult height, the ADHD group was 1.29 AE 0.55 cm shorter than the LNCG (p < .01, d = .21), and the comparisons of the naturalistic subgroups were significant: the treated group with the Consistent or Inconsistent pattern was 2.55 AE 0.73 cm shorter than the subgroup with the Negligible pattern (p < .0005, d = .42), and within the treated group, the subgroup with the Consistent pattern was 2.36 AE 1.13 cm shorter than the subgroup with the Inconsistent pattern (p < .04, d = .38). Conclusions: In the MTA follow-up into adulthood, the ADHD group showed symptom persistence compared to local norms from the LNCG. Within naturalistic subgroups of ADHD cases, extended use of medication was associated with suppression of adult height but not with reduction of symptom severity.
Introduction
The Multimodal Treatment Study of Children with attention-deficit/hyperactivity disorder (ADHD), known as the MTA, was initiated in 1994 (just before release of DSM-IV) and continued until 2013 (just before release of DSM-5), spanning the entire DSM-IV era. The background, design, methods, and findings from childhood to adolescence have been presented in over 100 publications (Appendix S1). This report describes outcomes of the MTA follow-up into adulthood (at an average age of 25 years).
The MTA began as a 14-month randomized clinical trial (RCT) to test hypotheses about four treatment strategies: medication management (Med), behavior modification (Beh), their combination (Comb), or treatment-as-usual for a community comparison (CC). After diagnosis with ADHD-combined type, 579 children (7.0-9.9 years old) were randomly assigned to treatment conditions and showed high compliance and adherence to the MTA protocol. Intent-to-treat (ITT) analyses revealed a significant relative benefit (greater decline in ratings of symptom severity) as well as relative cost (reduced height gain) in the groups with (Med and Comb) compared to without (Beh and CC) stimulant medication provided by-protocol for 14 months (MTA Cooperative Group, 1999) .
After the RCT, the MTA transitioned into an observational long-term follow-up (LTF), and analyses were performed to generate hypotheses for future studies (see Appendix S2). At 2 (MTA Group, 2004a , 2004b , 3 (Jensen et al., 2007) , and 8 (Molina et al., 2009 ) years after baseline, ITT analyses of the randomly assigned groups were continued and indicated the initial symptom-related benefit and growth-related cost dissipated after the 14-month treatment-by-protocol phase. During the LTF phase, medication use was monitored prospectively. This documented different patterns of starting and stopping medication resulting in convergence in the rates of medication use across the assigned treatment groups, generating the hypothesis that continued relative benefit and cost may be associated with continued use of medication (MTA Group, 2004b) . However, subsequent comparisons of naturalistic subgroups (see Swanson et al., 2007) with different patterns of extended treatment (i.e. no use, new use, inconsistent use, and consistent use of medication in childhood) showed that symptom severity was not significantly different for these naturalistic subgroups. This generated the hypothesis that symptom-related benefit may dissipate even when medication is continued. In contrast, childhood height was reduced in the naturalistic subgroup with consistent treatment. This generated the hypothesis that growth-related costs may not dissipate when medication is continued.
Here, additional hypothesis-generating analyses will be performed using adult outcomes based on the final assessment of the MTA. Methods developed by Swanson et al. (2001) will be used to focus on a primary outcome, to limit the number of statistical tests, and to apply contrast coding for planned comparisons. The primary outcome, adult symptom severity averaged across domains and sources, will be used instead of many outcomes (to limit the number of statistical tests). The end-point in adulthood will be analyzed, instead of trajectory into adulthood (to simplify interpretation of findings). Three planned comparisons of the four groups will be used instead of six pair-wise comparisons (to address efficiently the main questions): 'Do symptoms persist into adulthood?', 'Is there a significant long-term symptom-related benefit (e.g. reduced symptom severity) of extended use of medication compared to no use?', and 'Does continuous use of medication result in greater benefit than interrupted use?'. Following the Consolidated Standard of Reporting Trials (CONSORT) revised guidelines (Ioanndis et al., 2004) , parallel analyses will be performed to address the same questions about adult physical size and a possible growth-related cost (i.e. suppressed adult height).
Methods

Ethical guidelines
This research met the ethical guidelines of the United States National Institutes of Health and the multiple universities that participated in the study, and it adhered to the legal requirements for research of the United States and Canada.
MTA sample
The CONSORT diagram of the MTA is presented in Table 1 . Entry into the LTF phase occurred 2 years after baseline, when 540 of the ADHD participants from the RCT phase were assessed and 515 reconsented for the follow-up. At the same time, 289 local normative comparison group (LNCG) participants were recruited from the same schools as the ADHD cases and assessed with the same protocol. Following the precedent set by Molina et al. (2009) , 31 LNCG participants with a diagnosis of ADHD at recruitment were excluded, so only 258 were included in the analyses reported here. Participants were assessed eight times from 2 to 16 years after baseline. As shown in Table 2 , retention was high in childhood, adolescence, and adulthood. Previous analyses of adult outcomes (Howard et al., 2016) indicated MTA participants with and without complete data were not significantly different on most baseline demographic variables and 'missing at random' criteria were met.
Use of medication
Starting at the 14-month assessment and continuing through the 10-year assessment (or until participants were 18 years of age), the Services for Children and Adolescents Parent Interview (SCAPI: Jensen et al., 2004) ) were multiplied by 2. If an IR and an SR formulation were administered on the same day, the sum of daily ME doses was used. Nonstimulant medications were excluded. The total ME dose for each interval was estimated as the product of the days treated times the daily dose. The totals were summed for the six intervals from baseline to the 10-year assessment to estimate the cumulative ME dose from childhood through adolescence.
Furthermore, a minimum ME regimen (at least 10 mg/day for at least 50% of days since the previous assessment) was used to classify treatment during each assessment intervals as '≥ minimal' or '< minimal' (see Jensen et al., 2007) . Rather than representing adequate or optimal treatment for all cases, this was intended to avoid exclusion of regimens based on low doses that might be effective for a few cases and regimens with medication administered only on school days (i.e. with planned drug holidays). Extending a previous method , sequences of intervals above or below the cutoff were used to define three long-term patterns of prospective treatment with medication from childhood through adolescence: Consistent (≥ minimal in all intervals), Inconsistent (≥ minimal in some but not all intervals), and Negligible (< minimal in all intervals). Prior use of medication before entering the MTA was documented in the baseline assessment, but the SCAPI was not administered at baseline to provide the same detailed information on prior as for prospective treatment. Prior Status was specified as a binary variable based on the presence or absence of a history of prior treatment with stimulant medication.
Outcomes
In adulthood (i.e. at assessments 12, 14, and 16 years after baseline), the primary outcome was symptom severity measured by the Conners Adult ADHD Rating Scale (CAARS: Young adult outcomes in the MTA Conners, Erhardt, & Sparrow, 1999) , which was completed by two informants (or sources) to provide parent-ratings and self-ratings. The CAARS includes items for the 18 DSM-IV ADHD symptoms, each rated on a 4-point severity scale (0 = not at all to 3 = very much). For both sources (and within the ADHD group and the LNCG), average rating- Molina et al. (2012) , with three levels (1: one-parent household and no college-educated parent; 2: either two-parent household or at least one college-educated parent; 3: two-parent family and at least one college-educated parent). d IQ was higher in the LNCG than in the ADHD group, but based on precedent (see Barkley et al., 2008 and Sibley et al., 2012) A composite measure (CAARS-avg) was created to reflect symptom persistence in adulthood by averaging parent-and self-ratings to capture source convergence (Kraemer et al., 2003) and to increase precision of measurement (Swanson et al., 2001 ). Typically, self-ratings by children with ADHD are lower than parent-ratings (see Owens, Goldfine, Evangelista, Hoza, & Kaiser, 2007) , but it is unclear whether the difference continues (see Sibley et al., 2012) or dissipates (see Barkley, Murphy, & Fischer, 2008) in adulthood. To evaluate this, a second composite measure (CAARS-diff) was created to reflect source divergence by taking the difference of parent-and selfratings of symptom severity.
At clinic visits, MTA staff measured height (in cm) with stadiometers, as well as weight (in kg) with digital scales. For comparison to critical studies in the literature (i.e. Wilens, 1998 and Swanson et al., 2007) , norms for the United States (Kuczmarski et al., 2002) were used to transform the absolute (raw score) to a relative (z-score) measure adjusted for age and sex.
Analyses
Using the statistical analysis system (SAS, Cary, NC) general linear model (GLM) program, simple one-way analyses of the primary outcome (CAARS-avg) and secondary outcome (Height-cm) were performed, using a between-group factor with four levels: Consistent, Inconsistent, Negligible, and LNCG. Sex and Age were included to evaluate possible gender and developmental effects. For Height-cm, Mid-Parent height (average z-score) was included to account for expected genetic effects. Comparisons of the groups were made using the SAS-GLM estimates of least square means (LSMs) adjusted for the other factors in the model.
To decompose a significant Group effect, three planned comparisons (see Appendix S3) were used instead of six (all possible) paired-comparisons. This limited the number of comparisons and addressed critical questions specified in the literature. As recommended by Barkley et al. (2008) , a normbased comparison (i.e. ADHD vs. LNCG) was used to provide an estimate of symptom persistence in adulthood. As recommended by Spencer et al. (1998, p. 503) , a comparison of '. . . treated children with ADHD with untreated children, and not with unaffected control subjects' was used to differentiate treatment and disorder effects, with the treated group represented by the pooled naturalistic subgroups with Consistent or Inconsistent treatment and the untreated group represented by the naturalistic subgroup with Negligible treatment. As recommended by Faraone, Biederman, Morley, and Spencer (2008, p 994) , to evaluate '. . . continuous treatment from childhood to adulthood' the group with treatment through age 18 (the naturalistic subgroup with Consistent treatment) was compared to a group with interrupted treatment (the naturalistic subgroup with Inconsistent treatment). Each comparison represents a difference between two groups, which was standardized by dividing by the pooled standard deviation (RMSE, the square root of the mean square error in the model defined for the SAS-GLM analysis of the outcome measure) to estimate effect size (Cohen's d).
Within the ADHD group, supplementary regression analyses were performed to address effects of cumulative ME dose on adult outcomes. This approach was suggested by Charach, Figueroa, Chen, Ickowicz, and Schachar (2006, p 419) , who proposed that height suppression would not '. . . become statistically significant until the dose of MPH is ≥2.5 mg/kg/ day for ≥4 years'. In the MTA, cumulative ME dose was specified as absolute instead of relative dose, and escalation over time with increasing size was not observed, as implied by the longitudinal mg/kg dose. For a typical case in the MTA (e.g. an 8.4-year old with an average weight of 30.5 kg at baseline), the high 2.5 mg/kg dose would be 76.5 mg/day. For 4 years, this would result in a cumulative ME dose of 111,325 mg, but over 10 years the cumulative ME dose would be much higher (i.e. 278,313 mg). To accommodate such a wide range (e.g. 0-300,000 mg), cumulative ME dose was dividing by 10,000, and the natural logarithm (after adding 1 to avoid 0) was used as the predictor in the regression analysis. As in the analyses of Group (see above), Age and Sex were included as factors in the regression analyses of CAARS-avg and Height-cm, and also Mid-Parent Height was included in the analysis of Height-cm.
Results
By the 12-year assessment point, all participants in the MTA were beyond age 18 (and thus in adulthood), so retention was based on the percentage having at least one observation from this point forward. This was higher than the percentage observed at any one assessment point, as some participants returned to the follow-up after missing an earlier assessment. As shown in Table 2a , observations in adulthood were available for 92.4% (476/515) of the ADHD and 93.4% (241/258) of the non-ADHD LNCG participants consented for the LTF, representing 82.2% (476/579 for the ADHD group) and 83.4% (241/289 for the LNCG) of those recruited for the study. The final assessments in adulthood were used for all participants, which were primarily from the 16-year assessment (88.0% for the ADHD group and 92.1% for the LNCG), with progressively fewer from the 14-year (8.6% and 5.8%) and 12-year (3.4% and 2.8%) assessment points.
Prospectively gathered information from the SCAPI was used to estimate patterns of extended use of medication for the 476 ADHD cases. As shown in Table 2b , in adolescence there was a fourfold decrease in the overall percentage of the ADHD cases with >minimal medication use at successive assessment points (i.e. from 59.2% at the 3-year assessment to 14.3% at the 10-year assessment). For the individual patterns based on sequences of use from childhood (baseline) through adolescence, 23.5% of the ADHD cases had the Negligible pattern (< minimal in all intervals), 69.1% had the Inconsistent pattern (≥minimal in some but not all intervals), and 7.4% had the Consistent pattern (≥minimal in all intervals). For these naturalistic subgroups, the prospective average cumulative ME doses were 2,153, 60,567, and 117,102 mg.
As shown in Table 2b , at the end of the 14-month treatment-by-protocol RCT, the rates of medication use were dramatically different for the four assigned treatment groups (e.g. 90.2% for Med to 13.9% for Beh), but then converged in adolescence, resulting in 10-year averages for cumulative ME dose that were similar but not identical (e.g. 58,986 mg for Med and 41,140 mg for Beh). Before performing the analyses of naturalistic subgroups, ITT analyses of the initially assigned treatment groups were performed to evaluate possible 'sleeper effects'. However, there were no reemergent significant assigned treatment group differences: the four assigned treatment groups did not differ significantly on average symptom severity ratings (Med = 0.93, Comb = 0.91, Beh = 0.94, and CC = 0.90) or adult z-height (Med = 0.21, Comb = 0.10, Beh = 0.26, and CC = 0.18). The critical MTA Medication Algorithm (Med + Comb vs. Beh + CC) contrast remained nonsignificant, despite a nontrivial enduring difference (>16,000 mg) in cumulative ME dose (see Table 2b ).
As shown in Table 2c , the naturalistic subgroups did not differ significantly on most demographic variables assessed in the children at baseline, including age at entry into the MTA, percentage male, symptom severity (except for slightly lower parent-ratings for the Negligible subgroup), or birthweight. However, the naturalistic subgroups differed (p < .05) on some of the demographic variables: the Consistent naturalistic subgroup had significantly higher family income, greater household advantages, and higher percentage of White participants. The LNCG differed from the overall ADHD group and was similar to the Consistent naturalistic subgroup with higher income and greater household advantages. As these differences were not predicted or considered during the design phase of the MTA to set the sample size and statistical power (see Kraemer, 2015) , these variables were not included initially as covariates, but subsequently they were included separately as possible moderators of findings in the initial analyses of the outcome variables.
Analysis of primary and secondary outcomes
The analyses of symptom severity (CAARS-avg and CAARS-diff) and adult height (Height-cm and Height-z) outcomes are shown in Table 3 . The three planned comparisons (ADHD vs. LNCG; Consistent or Inconsistent vs. Negligible; Consistent vs. Inconsistent) are shown in Table 3 (for more detail, see Appendix S3). The observed means and standard deviations for the four levels of the between-group factor (as well as for the overall ADHD group based on the pooled naturalistic subgroups) are shown in Figure 1 . The SAS-GLM analyses also provided estimates of LSMs (estimates of marginal means over a balanced population) as well as observed means. The LSMs (see Table 3 , footnotes c and f) were used for the planned comparisons.
In the analysis of CAARS-avg, the Group factor was significant (p < .0001), but effects of Age and Sex were not significant. As shown in Table 3a and Figure 1a , the comparison of diagnostic groups (ADHD vs. LNCG) was significant (p < .0001), due to a higher value for the parent/self-report average rating in the ADHD group than the LNCG (by 0.51 AE 0.04), with a large effect size (d = 1.11). Within the ADHD group, the medication-related comparisons of the naturalistic subgroups were not significant. In analyses of CAARS-diff, the Group factor was significant, and the ADHD-LNCG comparison revealed significant (p < .0001) parent/selfreport discrepancy (by 0.21 AE 0.04), with a medium effect size (d = .61), due to higher parent-than selfratings in the ADHD group but not in the LNCG (see Figure 1a) . Within the overall ADHD group, the two medication-related comparisons of the naturalistic subgroups were not significant.
In analysis of Height-cm, the effect of the Group factor was significant (p < .0001). Age was not significant, as expected in adulthood (age 25) when final height has been achieved, but Sex and Mid-Parent Height were significant. As shown in Table 3b and Figure 1b , the ADHD group was significantly (p < .01) shorter than the LNCG (by 1.29 AE 0.55 cm or about 0.51 of an inch) with a small effect size (d = .21). Within the overall ADHD group, the two medicationrelated comparisons of the naturalistic subgroups were significant with small to medium effect sizes for Height-cm: (a) the average was significantly (p < .0005, d = .42) lower for the treated ADHD group (the pooled Consistent and Inconsistent subgroups) compared to the Negligible subgroup (by 2.55 AE 0.73 cm or about 1 inch) and (b) the average was significantly (p < .0378, d = .38) lower for the Consistent compared to Inconsistent subgroup (by 2.36 AE 1.13 cm or about 0.93 inch). To supplement the three planned comparisons, the six pairedcomparisons are provided in Appendix S3, which show a 4.7 cm difference between the extreme subgroups (Consistent vs. Negligible).
Analyses of Height-z showed similar significance levels and effect sizes for relative height (see Table 3b and Figure 1c ) as for absolute height adjusted for Sex and Age. The Negligible subgroup had a LSM of 0.434, which indicated that the 'untreated' clinical control group was taller than the population average (z-score = 0). In the previous report , a speculative hypothesis was proposed that the larger-than-average size of the untreated ADHD cases may be associated with a theoretical biological factor (a dopamine deficit), which is expected to increase growth. However, also the LNCG was taller than the population average (with a LSM of 0.351), confirming a previous finding in childhood and suggesting secular factors (e.g. the recruitment methods, the site locations, etc.) contributed to increased height compared to the population average.
All analyses were repeated with covariates added for Household Advantage, Income, and Race/Ethnicity. For symptom severity, Income was significant (p < .03), but Household Advantage and Race/ Ethnicity were not significant. For adult height-cm, Income, Household Advantage, and Race/Ethnicity were not significant. For symptom severity and adult height-cm, analyses were repeated with covariates Ratings of symptom severity by both sources were required for the composite scores (Conners Adult ADHD Rating Scale (CAARS) parent/self-report-average and parent/self-report difference). Ratings from both sources were available in adulthood for n = 233 participants in the local normative comparison group (LNCG) (90.5%) and for n = 439 participants in the attention-deficit/ hyperactivity disorder (ADHD) group (85.2%), with n = 102 (N), n = 307 (I), and n = 30 (C) in the subgroups. b Analyses were performed with SAS-GLM program, using the end-point observations in adulthood for each participant. For the Group factor, four levels were used: LNCG (L), Negligible (N), Inconsistent (I), and Consistent (C). c The GLM least square mean (LSM) estimates of symptom severity (adjusted for other factors in the model) for the four groups were C = 0.929, I = 0.940, N = 0.876, L = 0.420 (for CAARS-avg) and C = 0.198, I = 0.159, N = 0.138, L = À0.055 (for CAARS-diff). d For the three comparisons, contrast coding was used to combine the four LSM estimates, with the LSMs either equally ('unweighted') or proportionally weighted by the subgroup sample size/total sample size of the subgroups being combined (see Appendix S2). In the GLM analyses, the 'root mean square error' (RMSE) for CAARS-avg was 0.4619, for CAARS-diff was 0.3483, for Height-cm was 6.145 and for Height-z was 0.8816. e Some participants were assessed by telephone instead of at a clinic visit. Clinic visits occurred and height was measured for n = 221 of the LNCG (85.7%) and n = 402 of the ADHD group (78.1%), with n = 92 (N), n = 276 (I), and n = 33 (C) in the subgroups. f The LSM estimates of adult height for the four groups were C = 168.3, I = 170.7, N = 173.0, L = 172.3 (for Height-cm) and C = À0.226, I = 0.106, N = 0.434, and L = 0.351 (for Height-z).
g These analyses included the ADHD participants with information from the Services for Children and Adolescents Parent Interview (SCAPI) on the use of medication. As described in the text, the natural logarithm of cumulative ME dose of medication (after dividing by 10,000 and adding 1).
Bold values indicate the significance at p > 0.05.
added (whether they were significant or not), and significance levels and effect sizes for outcome variables were essentially unchanged. Weight-kg was not a primary outcome, but exploratory analyses revealed that the ADHD group was significantly (p < .0001) heavier (by 4.6 AE 1.78 kg) than the LNCG (see Figure 1b) . Unlike for Height-cm, the medication-related comparisons of naturalistic subgroups were not significant (p > .05). Analyses of BMI-m/kg 2 paralleled those for Weight-kg, with Observed means and standard deviations from SAS-GLM analyses for the four groups (LNCG, Negligible, Inconsistent, and Consistent). Least Square Means (LSM), adjusted for other factors in the models, were used for the three planned comparisons (ADHD vs. LNCG; Consistent or Inconsistent vs. Negligible; Consistent vs. Inconsistent). The LSM estimates for the four groups are presented in footnotes of Table 3 . LNCG, local normative comparison group [Colour figure can be viewed at wileyonlinelibrary.com] significantly higher body mass for the ADHD group than the LNCG, but neither comparison of the naturalistic subgroups was significant. Analyses of relative measures showed similar significance levels and effect sizes as analyses of absolute measures adjusted for Sex and Age. The naturalistic subgroups were divided further based on history of prior use of medication before entry into the MTA (Prior Status, see Table 2b ). The naturalistic subgroups differed in the percentage of participants with prior treatment with medication (28% for Negligible, 41% for Inconsistent, and 67% for Consistent). Prior Status was added as a factor in analyses with three levels of Group (without the LNCG). Neither Prior Status nor its interaction with Group was significant in any of the analyses of adult outcome (see Appendix S4).
Regression analyses
Regression analyses of cumulative ME dose in the ADHD group are shown in Table 3c for adult height. Scatter plots of the observed outcomes are presented for CAARS-avg (Figure 2a ), Height-cm (Figure 2b) , and Height-z (Figure 2c ). For CAARS-avg, the slope was positive but not significant (+0.04 AE 0.03 cm/ ln-unit, p = .14), suggesting cumulative ME dose was not related to symptom severity in adulthood (see Figure 2a) . Neither Age nor Sex was significant.
For Height-cm, the slope was negative and significant (À1.02 + 0.34 cm/ln-unit, p < .003), suggesting an increase in cumulative dose was associated with lower adult height (see Figure 2b) . For a cumulative ME dose of 100,000 mg, the regression equation predicts height suppression in adulthood of 2.4 AE 0.33 cm or almost an inch. Age was not significant, but Sex was significant (with female participants 14.26 cm shorter on average than male participants -see Table 3c ). Regression analysis of the relative measure adjusted for age and sex (Height-z, see Figure 2c ) showed a similar effect of cumulative ME dose (i.e. a significant slope) as in the analysis of the absolute measure (Height-cm) with Age and Sex included as factors.
Analyses with covariates added for Income, Household Advantage, and Race/Ethnicity were performed, but none of these were significant or changed the findings. Analyses were repeated with Prior Status (and its interaction with cumulative ME dose) added as predictors, but neither was significant (see Appendix S4).
In additional analyses for weight and body mass, the slopes were not significant for raw scores (Weightkg and BMI-m/kg 2 ) or for standard scores (Weight-z and BMI-z), suggesting cumulative ME doses was not related to these outcome measures in adulthood. These findings are consistent with the nonsignificant medication-related comparisons of the ADHD subgroups for these outcomes (Figure 1 ).
Discussion
The findings from LTF phase of the MTA address the three critical questions specified in the introduction about long-term symptom-related and growthrelated outcomes of children with ADHD and about possible long-term benefits (adult symptom reduction) and costs (adult height suppression) associated with the treatment of ADHD with stimulant medication. First, comparisons of the ADHD group to contemporary (as well as prospective) norms from unaffected classmates (the LNCG) suggest significant persistence of the disorder due to higher levels of symptom severity in adulthood. Second, the comparisons of ADHD-treated and ADHD-untreated groups suggest that in the long-term, symptom-related benefit of treatment with medication may dissipate and not remain significant but growth-related cost may remain statistically significant in adulthood. Third, the comparisons of groups with continuous and interrupted use of medication from childhood through adolescence suggest greater treatment may not result in greater symptom-related benefit but may result in greater growth-related cost. These findings add to the literature and to some controversies about long-term outcomes and long-term effects of treatment of ADHD.
The significant symptom persistence effect described here was based on a dimensional outcome (a scaled outcome based on effect size) instead of a traditional categorical outcome (a binary outcome based on a cutoff). Kraemer and Kupfer (2006) discussed issues about when each of these alternative approaches should be used, and described the decision as a '. . . struggle between statistical considerations favoring dimensional outcomes and clinical consideration favoring categorical outcomes'. One reason for using the dimensional approach was to maximize statistical power for detecting possible long-term benefits and costs of medication. A categorical approach (based on symptom count rather than symptom severity) was presented in a companion article to enhance clinical relevance related to symptom persistence. Sibley et al. (2017) described persistence rates for combinations of three factors: cutoff criteria (six symptoms for DSM-IV, five for DSM-5, and four for statistical norms), source (parent-report or self-report), and method (interview or rating scale). A broad range (from 1.9% to 61.4%) highlighted the controversy about which combination to use. Hechtman et al. (2016) evaluated the validity of one combination that is currently clinically relevant (DSM-5 criteria, rating scale method, and combined sources, with a persistence rate of 49.9%) and showed significant differences between Persistent and Desistent subgroups on functional adult outcomes assessed in the MTA (educational, occupational, sexual, emotional, and substance use). These large dimensional and categorical effects of symptom persistence are consistent with the notion that ADHD is a chronic condition. This adds to the controversy about the magnitude of persistence of ADHD in adulthood, which depends on how it is measured (see Barkley, Fischer, Smallish, & Fletcher, 2002 and Mick, 2006) . Also, this confirmed other findings in the literature on the effect of stimulant medication on persistence of ADHD, which was not significant in one of the earliest long-term follow-up studies (Weiss, Kruger, Danielson, & Elman, 1975) or in one of the most recent (Biederman, Petty, Clarke, Lomedico, & Faraone, 2011) .
The significant source discrepancy effect described here adds to the literature on another controversial issue. For example, Barkley et al. (2008) followed (to age 27) a group of 158 cases (diagnosed with hyperactivity in 1979-1980 before the criteria were established for diagnosing ADHD) and 81 nonaffected controls, and concluded '. . . selfreported information [converges with] parent/other reported information' (p. 66), but Sibley et al. (2012) followed (to age 20) a group of 200 cases (diagnosed with ADHD from 1986 to 1997) and 121 nonaffected controls, and concluded '. . . young adults with ADHD tended to underreport symptoms' (p. 1). If source convergence occurs, when is this manifested? As reported here for the MTA, using a larger sample, a dimensional outcome with statistical advantages, and follow-up to age 25, source discrepancy was still significant in adulthood. For categorical outcomes, Sibley et al. (2017) also found symptom persistence to be 40-137% higher for parent-report than self-report depending on the combination of factors used to classify cases. These findings from the MTA are consistent with the hypothesis that self-report of symptoms remains far below parent-report in early adulthood (at least to age 25).
The significant height suppression effect described here adds to the controversy about a possible growthrelated cost of long-term use of medication. The findings from the MTA are not consistent with many LTF studies in the literature (see below), but they are consistent with a recent study that was based on similar methods. Poulton et al. (2013) described a small clinical sample (n = 22 ADHD cases) selected for consistent use of medication from childhood to adolescence (i.e. average ME dose starting at 46 mg/ day with continuous treatment for an average of 7 years, suggesting a cumulative ME dose of 117,530 mg). For this naturalistic subgroup, average adolescent height (assessed between 14 and 16 years of age) was significantly (p < .01) lower (by 2.7 cm or more than an inch) than for a non-ADHD group (n = 132). For an equivalent comparison in the MTA, the height of Consistent naturalistic subgroup (n = 33) -with about the same cumulative ME dose (117,102 mg) -was compared to a non-ADHD group, the LNCG (n = 221). Average height in adulthood was significantly (p < 0,001, d = .65) lower (by 4.0 cm or about 1.5 inch). This replicates and extends the findings of Poulton et al. (2013) with a larger sample and longer follow-up.
The discrepancy with other LTF studies in the literature may be related to changes in the clinical use of medication over the past 50 years and differences in the average cumulative ME dose for treatment-as-usual. For example, most studies of ADHD and growth report average ME daily dose (mg/day) and average duration (years) for treated cases, and for some often-cited studies, the product provides an estimate of cumulative ME dose. For a clinical sample recruited in the 1960s (Kramer et al., 2000) , the product (31.2 mg/day 9 3.02 years) was 34,350 mg. For a clinical sample recruited in the 1970s (Klein & Mannuzza, 1988) , the product (44.9 mg/day 9 2.24 years) was 36,710 mg, indicating a slight increase in cumulative ME dose. For a population-based sample of ADHD cases identified from an epidemiological cohort in the 1980s (Harstad et al., 2014) , the product (26.2 mg 9 4.42 years) was 42,268 mg, indicating a substantial increase in cumulative ME dose over the decade from 1970 to 1980. However, none of these studies reported a significant difference in adult height between the treatment-as-usual ADHD group and a non-ADHD control group. To match the methods of these historical studies, the pooled group of treated cases with the Inconsistent or Consistent pattern (i.e. with treatment-as-usual in the LTF during the 1990s and 2000s) was considered. The cumulative ME dose was 66,003 mg, representing a 92% increase from the 1960s, an 80% increase from the 1970s, and a 56% increase from the 1980s. Compared to the LNCG, adult height was significantly lower (by 2.0 cm, p < .01), suggesting height suppression with a small to medium effect size (d = .32). The cumulative exposure hypothesis (see Charach et al., 2006) and this post hoc finding from the MTA generate a hypothesis about the discrepancy with previous studies: a secular trend of increasing cumulative ME dose occurred from the 1960s to the 1990s, and in the MTA (initiated in the 1990s), the average exposure was sufficient to produce significant height suppression in cases treated with medication.
The MTA findings generate hypotheses about other prominent studies that do not report cumulative ME dose. For example, based on a 10-year follow-up in a study initiated in the 1980s, Biederman, Spencer, Monuteaux, and Faraone et al. (2010) reported that duration of treatment (dose was not available) was not significantly related to adult height. However, in a previous report on substance use outcomes in the male subjects, Biederman et al. (2008) reported that 27% of the ADHD cases were untreated, but this naturalistic subgroup was not excluded or compared to the treated subgroup as recommended by Spencer et al. (1998) . Furthermore, they reported that many of the participants (50%) were treated for <2 years, suggesting 23% of the sample had extended use of medication for 2 years or more. The MTA findings generate the hypothesis that in a post hoc analysis, the naturalistic subgroup of males with extended use of medication would show height suppression compared to the clinical control group of untreated cases. In addition, consider the example provided by Peyre et al. (2013) . In a large representative sample of over 35,000 adults identified in [2004] [2005] , adult ADHD cases with (n = 216) and without (n = 591) use of stimulant medication were identified. Peyre et al. (2013) reported that these subgroups did not differ in adult height. However, they also reported the average age of treatment initiation was 15.9 years, which likely resulted in a high percentage of cases with treatment only after most growth was attained. The MTA findings generate the hypothesis that a subgroup of cases with treatment initiated in childhood and continued through adolescence would show height suppression. Thus, findings from the MTA suggest alternative analyses that may be warranted before accepting the null hypothesis that extended use of medication does not suppress adult height.
Implications for guidelines
The most recently published guidelines (American Academy of Pediatrics, 2011) recommend expanding the diagnosis and treatment of ADHD and using stimulant medication as first-line treatment for adolescents as well as school-aged children. As this would increase the average duration of treatment and cumulative ME dose of medication in some individuals, the MTA findings suggest growth-related costs may increase. This possibility may need additional emphasis, similar to the contemporary European guidelines for managing adverse side effects of medication for ADHD (Graham et al., 2011) , which presciently highlight this relevant issue: 'It is possible that the effects of stimulants on growth are dosedependent. Significant effects on weight and height may require average doses of methylphenidate exceeding 1.5 mg/kg per day which are given continuously' (p 24). The regression analyses of the MTA support this speculation. Revised guidelines could address strategies for reducing cumulative ME dose. In the RCT phase of the MTA, combining behavioral intervention with the use of medication reduced average daily dose by 20% without a reduction in efficacy (see Vitiello et al., 2001) , and recently, Pelham et al. (2016) showed that initiating treatment with low-intensity psychosocial treatment before adding medication reduced the daily dose on school days by 25% without a reduction in efficacy. The findings of the MTA suggest that these strategieswhich appear to achieve full short-term symptomrelated benefits in childhood -may reduce long-term growth-related costs in adulthood.
Limitations
First, as for any observational study, the findings from the LTF phase of the MTA should be used to generate hypotheses and not be interpreted as tests of hypotheses. Without protection by randomization, the suggestions based on comparisons of naturalistic subgroups are speculative, both for significant effects and for nonsignificant effects. It remains unclear how much selection or confounding factors contribute to or account for the findings reported here. For example, the cases receiving consistent treatment with medication may have been the most severe cases based on factors not evaluated in the MTA, and if so, this could have masked benefit. Therefore, the possibility of long-term symptomrelated benefits should not be excluded by the hypothesis-generating analyses of the LTF phase of the MTA. Instead, the findings should be used to design future studies to test refined hypotheses about alternative treatments and to identify alternative follow-up methods that may reveal some longterm benefits of medication in some cases in some conditions. Second, with alternative designs, the findings of the MTA may have been different. For example, treatment provided as usual in the follow-up likely resulted in lower doses and fewer adjustments than treatment-by-protocol would have provided. If treatment according to the MTA medication algorithm had continued (including monthly 30-minute physician visits, with adjustments to the medication regimen based on regular review of current status based on parent and teacher ratings), the significant relative benefit of medication observed in the RCT phase (relative reduction of symptom severity) may have persisted into early adulthood. In addition, the acute effect of medication in adulthood was not evaluated. For example, a placebo substitution manipulation was not used to evaluate the cases that continued to use medication in adulthood. If this design had been incorporated into the LTF phase of the MTA, support for continued benefit of medication may have emerged due to increased symptom severity on placebo, even though when on medication, overall symptom severity may not have been reduced compared to other subgroups.
Third, the nonsignificant effect of medication on the primary outcome reported here (symptom severity) may not hold for other outcomes. Other studies have reported long-term benefits of stimulant medication on nonsymptom outcomes, including reduction in substance use in adolescence (e.g. see Wilens, Faraone, Biederman, & Gunawardene, 2003 for a review). However, apparent protective effects in adolescence may not be manifested later in adulthood (see Biederman et al., 2008) . Mannuzza et al. (2008) suggested that a protective effect on substance use in adulthood may depend on starting stimulant medication early, and this hypothesis was supported by recent epidemiological studies of medication records in Norway (Dalsgaard, Mortensen, Frydenberg, & Thomsen, 2014 ) and a high-school survey in the United States (McCabe, Dickinson, Brady, West, & Wilens, 2016) . Analyses of MTA substance use outcomes in adulthood are in progress.
Fourth, the large symptom persistence effect and the medium source discrepancy effect reported here were based on the CAARS rating scale, which in the nonclinical population (i.e. the LNCG) is not normally distributed. The impact of this on the significance levels and effect sizes reported here is unclear. Further evaluation of this is planned for future reports. These effects were also observed in early adulthood (at an average age of 25 years), and if the MTA LTF had been continued into midadulthood, it is possible that smaller or nonsignificant effects of symptom persistence and source discrepancy may have been observed (see Klein et al., 2012) .
Fifth, the significant association of extended use of medication with suppressed adult height may not be causal. The formation of naturalistic subgroups using SCAPI-based sequences of extended use of medication may have resulted in selection biases or confounding (see Hernan, Hernandez-Diaz, & Robins, 2004) related to physical size as well as to severity (see above). For unknown reasons, selective treatment of ADHD cases that are constitutionally short may have occurred. If so, then the height suppression reported here would be due to characteristics of the treated cases rather than to their treatment with medication. An analysis was performed to evaluate the possible association of future use of medication with the baseline height of the naturalistic subgroups described here (i.e. before pattern of medication use could have caused height suppression). This did not show a significant effect of prospective medication use on baseline height, but the sample size of the MTA was not sufficient to evaluate fully multiple factors and their possible interactions (age, sex, maturation, and prior use of medication). A previous analysis (see Swanson et al., 2007) noted that among the ADHD cases without a history of prior use of medication before entry into the MTA, those remaining untreated prospectively during childhood were already about 1 cm taller at baseline than those destined to receive consistent prospective treatment. To compensate for this, Swanson et al. (2007) suggested a reduction in estimates of medication-related height suppression in late childhood by 1 cm (i.e. from about 3 to 2 cm). A similar adjustment may be prudent for estimates of height suppression in adulthood.
Sixth, the lack of complete information on prior medication use limited the analysis of this important factor (see Poulton & Nanan, 2008) . In analyses of the naturalistic subgroups, neither the main effect of Prior Status nor the interaction of Prior and Prospective use of medication in the MTA (defined by different patterns of extended use by the naturalistic subgroups or by cumulative ME dose) had a significant effect on adult height. However, the direction of small effects (lower intercept and reduced slope in cases with a history of prior use of medication) suggests with a larger sample, the effect of Prior Status may reach significance.
Seventh, timing of treatment may affect growth mediated by different underlying biological processes (e.g. growth hormone and sex hormones). Differential exposure to medication during childhood and adolescence were not evaluated here, as suggested by the tempo hypothesis proposed by Spencer et al. (1998) . Also, analyses using mathematical modeling to identify effects of medication on milestones of growth (i.e. height, height velocity, and age of the 'take-off' or 'peak' points of the adolescent growth spurt) were not reported here. Analyses of trajectory of height from childhood to adulthood (rather than analyses of the adult endpoint) may provide additional information on mechanisms involved in suppression of final adult height. These possibilities will be addressed in future reports.
Eighth, outcomes related to weight and body mass were considered secondary here. In the limited analyses of these outcomes, the findings from the planned comparisons are consistent with the findings from some studies in the literature about disorder-related effects, such as those suggesting adults with ADHD are at risk for obesity (see Cortese et al., 2008) , overweight (see Hanc et al., 2014) , and increased body mass (Schwartz et al., 2014) . However, the findings from the MTA generate the hypothesis that extended use of medication in childhood and adolescence may increase adult BMI by suppressing adult height but not adult weight.
Ninth, the SCAPI was used to establish the naturalistic subgroups, but the use of this instrument has several limitations. The SCAPI was a new measure developed for the MTA, and information was not available on reliability and validity of parent reports of medication use. The parent-based interview was not administered after the age of 18 years, so information on use of medication in adulthood was not obtained. The SCAPI-based patterns of extended medication use were based on logical analysis of all possible sequences across the assessment intervals from childhood through adolescence, and recently developed data-driven classification methods to establish subgroups with different trajectories of medication use (see Schweren et al., 2016) were not evaluated here.
Conclusions
The observational LTF phase of the MTA generated hypotheses that could be tested in future studies. The findings of the MTA suggest the following: childhoodonset ADHD is a chronic disorder with persistence of symptoms into adulthood; source discrepancy due to lower self-ratings than parent-ratings is manifested in early adulthood; and extended use of stimulant medication from childhood through adolescence is associated with suppression of adult height but is not associated with reduced symptom severity in adulthood.
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